June 28, 2024Open Access

Systemic treatment options for non-small cell lung cancer after failure of previous immune checkpoint inhibitors: a bayesian network meta-analysis based on randomized controlled trials

Key Points

Key points are not available for this paper at this time.

Abstract

Although immune checkpoint inhibitors (ICIs) have brought survival benefits to non-small cell lung cancer (NSCLC), disease progression still occurs, and there is no consensus on the treatment options for these patients. We designed a network meta-analysis (NMA) to evaluate systemic treatment options for NSCLC after failure of ICIs.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Wang et al. (Fri,) studied this question.

synapsesocial.com/papers/68e62c1bb6db6435875be5fb https://doi.org/https://doi.org/10.1186/s12865-024-00633-z

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial2016 · 4,781 citations
2<scp>TAM</scp> receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy2017 · 156 citations
3PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer2013 · 635 citations
4Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016 · 10,102 citations
5OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)2022 · 8 citations

Bookmark

View Full Paper